个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共6条记录   RECOMMENDATIONS OF THE LATIN AMERICAN NETWORK FOR THE STUDY AND TREATMENT OF NEUROPATHIC PAIN [作者：Rey, R; Arizaga, E; Verdugo, R; Vidal, O; Jreige, A; Juarez, H; Chinchilla, D; Colimon, F,期刊：Drugs of today, 页码：1-33 , 文章类型： Article，,卷期：2011年47-5] DIFLUPREDNATE FOR INFLAMMATORY EYE DISORDERS [作者：Mulki, L; Foster, CS,期刊：Drugs of today, 页码：327-333 , 文章类型： Article，,卷期：2011年47-5] Uveitis is the third leading cause of preventable blindness in the U.S. Topical administration of corticosteroids remains the mainstay in the management of acute autoimmune anterior uveitis. Difluprednate 0.05% ophthalmi... BUCINDOLOL: NEW HOPES FROM REVIEWING PAST DATA [作者：Fiuzat, M; O'Connor, CM,期刊：Drugs of today, 页码：347-351 , 文章类型： Review，,卷期：2011年47-5] beta-Adrenoceptor antagonists or beta-blockers are a cornerstone of therapy in chronic heart failure (CHF). Bucindolol hydrochloride is a fourth-generation beta-blocker in development for the treatment of CHF. Two trials... PSYCHOSIS IN PARKINSON'S DISEASE: THERAPEUTIC OPTIONS [作者：Hasnain, M,期刊：Drugs of today, 页码：353-367 , 文章类型： Review，,卷期：2011年47-5] This publication offers a review of the pharmacological interventions studied for Parkinson's disease psychosis. Before initiating drug therapy for psychosis, possible contribution of antiparkinsonian medications to psyc... URATE AS A MARKER OF DEVELOPMENT AND PROGRESSION IN PARKINSON'S DISEASE [作者：Constantinescu, R; Zetterberg, H,期刊：Drugs of today, 页码：369-380 , 文章类型： Article，,卷期：2011年47-5] Urate, a natural antioxidant and iron chelator, has emerged as a potentially promising compound that might prevent neurodegenerative disorders. However, hyperuricemia may cause gout and is associated with increased cardi... LAPATINIB DITOSYLATE: EXPANDING THERAPEUTIC OPTIONS FOR RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2-POSITIVE BREAST CANCER [作者：Awada, A; Saliba, W; Bozovic-Spasojevic, I,期刊：Drugs of today, 页码：335-345 , 文章类型： Article，,卷期：2011年47-5] Receptor tyrosine-protein kinase erbB-2 (HER2)-positive breast cancer is a specific entity with an aggressive behavior Trastuzumab, a monoclonal antibody targeting erbB-2 (HER2) deeply transformed the outcome in patients...